2. www.visiongain.com
Contents
1.1 The Point of Care (POC) Diagnostics Market Highlights
1.2 Chapter Outlines
1.2.1 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying In Vitro Diagnostics
2.2.1 FDA Classifications
2.2.2 IVD Classification in Australia
2.2.3 EDMA Classification
2.2.3.1 Clinical Chemistry: Not To Be Discounted
2.2.3.2 Immunochemistry
2.2.3.3 Haematology
2.2.3.4 Microbiology
2.2.3.5 Genetic Testing
2.2.3.6 Point Of Care Diagnostics: The Most Prominent Type
2.3 Diagnostics Regulation of the IVD and POC Market
2.3.1 FDA and CLIA Regulation of IVD and POC Tests
2.3.2 Regulation of IVD/POC Diagnostics in the EU: The EC (European Commission)
Classification
2.4 Regulation for In-Vitro Diagnostics and POC Diagnostics
1. Report Overview
2. Introduction to In-Vitro Diagnostics and POC Diagnostics
3. www.visiongain.com
Contents
2.4.1 Top Ten Challenges in Regulation for In-Vitro Diagnostics
2.4.2 Device Excise Tax: A Threat to the Diagnostics Manufacturers
2.5 Uses of Point of Care (POC) Diagnostics
2.6 Advantages and Disadvantages of POC Diagnostics
3.1 Scope of this Report
3.2 Point of Care Diagnostics in the IVD Market, 2013
3.3 The World Point of Care Diagnostics Market in 2013
3.3.1 Self Testing Constituted the Largest Segment in the POC Market by the Point of
Delivery
3.3.2 Point of Care Diagnostics Market Segmentation
3.4 The Global IVD Market: Sales Forecast, 2014-2024
3.4.1 Which Segments Will Drive the Global IVD Market in the Next 10 Years?
3.5 The Global Clinical Diagnostics Market Forecast, 2014-2024
3.6 The Global Point of Care Diagnostics Market: Sales Forecast 2014-2024
3.6.1 The Drive of Personalised Medicine
3.7 Market for POC Diagnostics Products: Leading Segments to 2024
3.7.1 Breakdown of the World Point of Care Diagnostics Main Submarkets: Changing Shares
2014-2024
3.7.2 Blood Glucose Testing Market Forecast 2014-2024
3.7.3 Infectious Diseases Testing Market Forecast 2014-2024
3.7.4 Rapid Coagulation Testing Market Forecast 2014-2024
3.7.5 Rapid Cardiac Marker Testing Market Forecast 2014-2024
3. The Point of Care Diagnostics Market, 2014-2024
4. www.visiongain.com
Contents
3.7.6 Cholesterol Testing Market Forecast 2014-2024
3.7.7 Pregnancy Testing Market Forecast 2014-2024
3.7.8 Other Segments Market Forecast 2014-2024
3.7.8.1 Cancer Diagnostics Will Be a Major Driver for This Segment
3.7.8.2 The Haematology Market Will Be Driven by Blood Gas Tests
3.7.8.3 A Recently Discovered Biomarker for Sepsis Can Set The Potential For A Future
Rapid Blood Test
3.8 Scope of the Point of Care Diagnostics Market
3.9 Which Point of Care Diagnostic Segment Holds the Greatest Potential?
3.9.1 The Point of Care Diagnostics Market: Drivers and Restraints 2014-2024
4.1 Regional Breakdown of the World IVD Market: Sales Forecast by Country 2014-2024
4.2 Regional Breakdown of the World Point of Care Diagnostics Market in 2013
4.3 The World POC Diagnostics Market: Regional Forecasts 2014-2024
4.4 How Will Regional Market Shares Change to 2024?
4.5 The US POC Diagnostics Market, 2013
4.5.1 The US Will Still Dominate the POC Diagnostics Market in 2024
4.5.2 The US POC Diagnostics Market Forecast 2014 - 2024
4.5.3 Healthcare Expending in the US
4.5.4 The US POC Diagnostics Market: Drivers and Restraints
4.6 The Leading European POC Diagnostics Markets: Sales Forecasts 2014-2024
4.6.1 Variation in the European POCT Markets, 2014-2024
4.6.2 The German POC Diagnostics Market Forecast, 2014-2024
4. Leading National Point of Care Diagnostics Markets 2014-2024
5. www.visiongain.com
Contents
4.6.3 The UK POC Diagnostics Market Forecast 2014-2024
4.6.4 The French POC Diagnostics Market Forecast 2014-2024
4.6.5 The Italian POC Diagnostics Market Forecast 2014-2024
4.6.6 The Spanish POC Diagnostics Market Forecast 2014-2024
4.6.7 The Netherlands POC Diagnostics Market Forecast 2014-2024
4.6.8 The Belgian POC Diagnostics Market Forecast 2014-2024
4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024
4.7 The Japanese POC Diagnostics Market Forecast 2014-2024
4.7.1 The Japanese POC Diagnostics Market Overview 2014-2024
4.8 The BRICK Nations POC Diagnostics Market
4.8.1 The BRICK Nations POC Diagnostics Market: Overview
4.8.2 How Will BRICK Market Shares Change to 2024?
4.8.3 The BRICK Nations POC Diagnostics Market Forecast 2014-2014
4.8.3.1 The Chinese POCT Market Overview: Advances in China Lead to Expansion of
the Market
4.8.3.1.1 The Chinese POC Diagnostics Market Forecast 2014-2024
4.8.3.2 The Indian POC Diagnostics Market Overview
4.8.3.2.1 The Indian POC Diagnostics Market Forecast 2014-2024
4.8.3.3 The South Korean POC Diagnostics Market Forecast 2014-2024
4.8.3.4 The Brazilian POC Diagnostics Market Forecast 2014-2024
4.8.3.5 The Russian POC Diagnostics Market Forecast 2014-2024
4.9 Rest of the World POC Diagnostics Markets Forecasts 2014-2024
4.9.1 Further Insights: Point of Care Diagnostics Approach for Developing Countries
6. www.visiongain.com
Contents
5.1 POC Blood Glucose Testing Market Overview
5.2 Global POC Blood Glucose Testing Market, 2013
5.3 POC Blood Glucose Testing Market Forecast 2014-2024
5.3.1 POC Blood Glucose Testing Market by Type of Meter
5.3.2 POC Blood Glucose Testing Market Segment by Components
5.3.2.1 POC Blood Glucose Testing Devices Currently Available in the Market, 2014
5.3.3 Leading Regional Markets in the POC Blood Glucose Testing Market, 2013
5.3.4 Leading Companies in the POC Blood Glucose Testing Market, 2014
5.3.4.1 Other Companies in the POC Blood Glucose Testing Market: Recent Advances
5.3.5 Market Prospects to 2024: Which Product Will Lead the Market?
5.3.5.1 Advantages and Disadvantages of the Current CGM Tests in the Market
5.4 Drivers and Restraints for the POC Blood Glucose Testing Market, 2014-2024
6.1 Global POC Coagulation Testing Market: Overview
6.2 Global POC Coagulation Testing Market in 2013
6.2.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market
6.3 Products Available in the POC Coagulation Testing Market, 2014
6.3.1 Patient Self Testing is a Fastest Growing Segment
6.4 POC Coagulation Testing Market Segment by Components
6.4.1 Test Strips Generate 85% of the Sales in the PT/INR POC Testing Market
6.5 POC Coagulation Testing Market by Type of Drug
5. Global Blood Glucose Testing Market, 2014-2024
6. Global Coagulation Testing Market, 2014-2024
7. www.visiongain.com
Contents
6.5.1 Anticoagulants
6.5.2 Heparins
6.5.3 Vitamin K Antagonists
6.5.4 Direct Thrombin Inhibitors
6.5.5 Direct Factor Xa Inhibitors
6.6 The POC Coagulation Testing Market by Regions, 2013
6.7 POC Coagulation Testing Market Forecast 2014-2024
6.8 Leading Companies in the POC Coagulation Testing Market, 2014
6.8.1 Roche Dominated the POC Coagulation Testing Market with CoaguChek XS System in
2013
6.8.2 Market Prospects to 2024: Who Will Be The Leading Product?
6.9 Drivers and Restraints for the POC Coagulation Testing Market, 2014-2024
7.1 Cardiac Marker Diagnostic Testing Market: Overview
7.1.1 The Majority of Cardiac Marker Testing is Conducted in Critical Care Settings
7.2 The Global Cardiac Marker Diagnostic Testing Market 2013
7.3 Cardiac Marker Diagnostic Testing Market Forecast 2014-2024
7.3.1 Leading Regional Markets in the Cardiac Marker Diagnostic Testing, 2013
7.3.1.1 Global Deaths Due to CVD in High, Middle and Low Income Countries, 2014
7.3.2 Leading Companies in the Cardiac Marker Diagnostic Testing Market, 2014
7.3.3 Cardiac Marker Diagnostic Tests Currently Under Development, 2014
7.3.3.1 cobas h232 Cardiac Marker (Roche)
7.3.3.2 QL Care Analyzer (CardioGenics)
7. Global Cardiac Marker Testing Market, 2014-2024
8. www.visiongain.com
Contents
7.3.3.3 Handheld Device (bioMerieux/Royal Philips Electronics)
7.3.4 Cardiac Marker Diagnostic Testing Market: Leading Products
7.3.5 Which Company is Dominating the Market?
7.3.6 A Leading Product: Abbott’s i-STAT
7.4 Drivers and Restraints for the Cardiac Marker Diagnostic Testing Market, 2014-2024
7.4.1 Challenges for the New Entrants in the Cardiac Markers Diagnostic Testing Market
8.1 POC Infectious Diseases Testing Market: Overview
8.2 Global POC Infectious Diseases Testing Market, 2013
8.2.1 Breakdown of the POC Infectious Diseases Testing Market by Diseases, 2013
8.2.1.1 Influenza/Flu
8.2.1.2 HIV
8.2.1.3 Hepatitis
8.2.1.4 Tuberculosis
8.2.1.5 Sexually Transmitted Diseases
8.3 The POC Infectious Diseases Testing Market: Leading Products 2014
8.3.1 HIV Leading POC Diagnostics Products, 2014
8.3.1.1 HIV Diagnostics Kits Approved by the FDA, 2014
8.3.2 The HIV Rapid Testing Market in the US, 2014
8.3.3 HIV POC Tests Pipeline, 2014
8.3.4 Driving Factors for Growth of HIV Rapid Testing: Past and Future
8.4 The Hepatitis POC Testing Market
8.4.1 First Rapid HCV Test Approved in the US
8. Global Infectious Diseases Testing Market, 2014-2024
9. www.visiongain.com
Contents
8.4.2 The Influenza POC Testing Market and Leading Companies, 2014
8.4.3 Driving Factors for Growth of Hepatitis Rapid Testing
8.4.4 POC Infectious Diseases Recent Trends
8.4.4.1 OraQuick Marker, OraSure Technologies: First OTC Home-Use Rapid HIV Test
Approved by the FDA
8.4.4.2 Determine HIV-1/2 Ag/Ab Combo Test, Alere: First Rapid Diagnostic Test to
Detect Both HIV-1 Antigen And HIV-1/2 Antibodies
8.4.5 Leading Regional Markets in the POC Infectious Diseases Testing
8.4.5.1 Infectious Diseases POC Testing: Regional Markets in 2013
8.5 Infectious Diseases POC Testing Market: Leading Companies 2014
8.6 The POC Infectious Diseases Testing Market Forecast, 2014-2024
8.7 Drivers and Restraints for the POC Infectious Diseases Testing Market, 2014-2024
9.1 The POC Pregnancy Testing Market: Overview
9.2 Global POC Pregnancy Testing Market, 2013
9.3 The POC Pregnancy Testing Market Forecast 2014-2024
9.3.1 The POC Pregnancy Testing Market: Leading Products 2014
9.3.2 Leading Companies in the POC Pregnancy Testing Market, 2014
9.4 Drivers and Restraints for the POC Pregnancy Testing Market, 2014-2024
10.1 Global POC Cholesterol Testing Market: Overview
10.2 The Global POC Cholesterol Testing Market in 2013
9. Global Pregnancy Testing Market, 2014-2024
10. Global Cholesterol Testing Market, 2014-2024
10. www.visiongain.com
Contents
10.3 The POC Cholesterol Testing Market Forecast 2014-2024
10.3.1 POC Cholesterol Testing Biomarkers: Overview
10.3.2 The POC Cholesterol Testing Market by Components
10.3.3 Recent Developments in the POC Cholesterol Testing Market, 2014
10.3.3.1 New Product 2014: Roche’s Accutrend Plus
10.3.4 POC Cholesterol Testing Market: Considerations in Production
10.4 Drivers and Restraints for the POC Cholesterol Testing Market, 2014-2024
11.1 Leadng POC Diagnostics Companies in 2014
11.2 Roche: Overview
11.2.1 Roche: Global Presence
11.2.2 Roche Diagnostics, 2014-2024
11.2.2.1 Roche Business Performance within the IVD Market, 2013
11.2.2.2 Roche Diagnostics Market Forecast 2014-2024
11.2.3 Roche Diagnostics: Key Launches Planned for 2014
11.2.4 Roche Diagnostics: POC Product Portfolio
11.2.5 Roche: Recent M&A Activity and Strategic Collaborations
11.3 Abbott: Continuously Transforming to Meet the Changing Needs
11.3.1 Abbott: Market Leader in the Coronary DES Sector
11.3.2 Abbott Diagnostics: Overview, 2013
11.3.2.1 Abbott Diagnostics: Leading Point-of-Care Platform
11.3.3 Abbott’s Fast Growing Diagnostics Division: Sales Forecast 2014-2024
11.3.4 Abbott Portfolio Sales and Recent Performance Analysis
11. Leading Companies in the POC Diagnostics Market, 2014
11. www.visiongain.com
Contents
11.3.5 Abbott: The i-STAT System
11.3.5.1 Recent M&A Activity and Strategic Collaborations
11.3.5.1.1 Abbott Laboratories Agreed to Acquire IDEV Technologies
11.3.5.1.2 Collaboration with Merck
11.3.5.2 Abbott IVD Segment: Strengths & Challenges
11.4 Siemens: A Highly Diversified Company
11.4.1 Siemens Healthcare: Prospects within the IVD Market
11.4.2 Siemens Healthcare: Sales Forecast 2014-2024
11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio
11.4.3.1 Siemens Healthcare Diagnostics Recent Trends, 2014
11.4.3.2 Recent M&A Activity and Strategic Collaborations
11.5 Alere Inc: A Strong Player
11.5.1 Alere Inc Performance Analysis in 2013
11.5.2 Alere Inc: Performance in Geographic Markets in 2013
11.5.3 Alere Inc.: Product Profile Overview
11.5.4 Alere’s Professional Diagnostics Market in 2013
11.5.5 Product Profile Recent Trends, 2014
11.5.6 Alere Market Forecast 2014-2024
11.5.7 Alere: Recent M&A Activity and Strategic Collaborations
11.6 Other Companies of Interest: Recent M&A Activity and Strategic Collaborations, 2014
12.1 Introduction
12.2 Drivers and Restraints for the POC Diagnostics Market
12. Qualitative Analysis of the POC Diagnostics Market, 2014-2024
12. www.visiongain.com
Contents
12.2.1 Commercial Drivers
12.2.2 Commercial Restraints
12.3 Strategic Review of the POC Diagnostics Market
12.4 Pestel Analysis
12.4.1 Political Factors
12.4.2 Economic Factors
12.4.3 Socio-Cultural Factors
12.4.4 Technological Factors
12.4.5 Environmental Factors
12.4.6 Legal Factors
12.5 P5F Analysis
12.5.1 Competitive Rivalry
12.5.2 Rivalry Among Competitors: [High] Diagnostics is a Promising Market
12.5.3 Potential Entrants into the POC Diagnostics Market
12.5.3.1 Threat of New Entrants: [Medium] Continuous Arousal of Innovations in the
POCT Market
12.5.4 Who Are The Latent Substitutes?
12.5.5 Threat of Substitutes: [Medium]New Technologies Might Limit the Need to Monitor
Diseases
12.5.6 Vertical Integration With Suppliers and Buyers
12.5.6.1 Power of Suppliers: [Medium] Increased Competition Outweigh Suppliers
12.5.6.2 Power of Buyers: [High] Demand and Health Systems Will Go Hand by Hand
12.6 SWOT Analysis and Strategies
12.6.1 Strengths: Timing is First
13. www.visiongain.com
Contents
12.6.2 Weaknesses: Awaiting Expanded Reimbursement Options
12.6.3 Opportunities: A Promising Market
12.6.4 Threats: Unmet Needs in the Low-Middle Income Countries
13.1 Interview with Dr. Terenzio Facchinetti, Director Business Development of UL Life and
Health, UL International GmbH, Germany.
13.1.1 Impact of Remote Access on the POCT Market
13.1.2 UL’s Life and Health Business Unit: A Global Independent Safety Science Company
13.1.3 The Importance of Standardization and Regulations for the POC Market
13.1.4 Recommendations for the Future of POC Diagnostics: What to Expect
13.2 Interview with Dr. Keith Batchelder, CEO and Founder of Genomic Healthcare Strategies
(GHS), USA.
13.2.1 Advantages of POC Diagnostics
13.2.2 Restraints of POC Diagnostics
13.2.3 About Genomic Healthcare Strategies
13.2.4 US has the Highest Potential for the POC Diagnostics Market
13.2.5 Remarkable Insights
13.3 Interview with Dr. David Huckle, President and CEO of Adams Business Associates (ABA),
UK.
13.3.1 Remarkable Understanding on the POC Diagnostics Market
13.3.2 The Expert’s Perspective: Drivers and Restraints for POC Diagnostics
13.3.3 Recommendations for the Future POC Diagnostics Market
13.3.4 Further Insights from Dr. Huckle: Leading Companies
13. Expert Opinions
14. www.visiongain.com
Contents
13.4 Interview with Dr. Stéphan Cohen-Bacrie, Co-director of the Multi-site Laboratory of
Immunohematology and Immunogenetics, French Blood Establishment, Burgundy-
FrancheComté, France.
13.4.1 The French POC Diagnostics Market: Experienced Perspective
13.4.2 Restraints in the POC Diagnostics Market
13.4.3 The Advantage of Molecular Diagnostics
13.4.4 Innovations in Rural Africa: POC-labs
13.4.5 R&D in Focus: The Syndromic Panels and Microfluidics-based Methods
13.4.6 Where is the POC Diagnostics Market Heading?: An Expert’s View
14.1 Overview
14.2 The POC Testing in the IVD Market
14.3 The World POC Diagnostics Market Forecast 2014-2024
14.3.1 Leading Regional Markets Forecast 2014-2024
14.4 The World POC Diagnostics Market Forecast 2014-2024
14.5 POC Diagnostic Segments: Positions in the Market 2014
14.5.1 Current Advantages in POC Diagnostics
14.5.1.1 Comparison with Laboratory Testing
14.5.2 Leading POC Diagnostics Companies, 2014
14.6 Commercial Drivers for the Adoption of POC Tests
14.6.1 Commercial Restraints in the POC Diagnostics Market
14.7 Challenges for POC Diagnostics
14.8 The Future of the POC Diagnostics and Concluding Remarks
14. Conclusions
15. www.visiongain.com Page 114
The Point of Care Diagnostics Market Forecast
2014-2024: Future Prospects for Leading Companies
diagnostics market. Furthermore international private hospitals and lab chains are acquiring private
Belgian laboratories.
Table 4.13 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR
(%) and CAGR (%), 2013-2024
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Belgium ($bn) 0.15 0.15 0.16 0.17 0.17 0.18 0.19 0.20 0.21 0.22 0.24 0.25
AGR (%) 4.5 4.6 4.7 4.8 4.9 5.1 5.2 5.3 5.4 5.4 5.5
CAGR (%) 2013-2018
CAGR (%) 2013-2024
4.7 2018-2024 5.3
5.0
Figure 4.15 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn) and
AGR (%), 2013-2024
Source: Visiongain 2014
4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024
The Swiss POC diagnostics market is estimated to grow from $0.14bn in 2013 to $0.18bn in 2018,
representing a CAGR of 4.1%. Growth between 2018 and 2024 is expected to exhibit a CAGR of
0
1
2
3
4
5
6
7
8
0.00
0.05
0.10
0.15
0.20
0.25
0.30
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales$bn
Year
Belgium ($bn) AGR (%)
Source: Visiongain2014
16. www.visiongain.com Page 143
The Point of Care Diagnostics Market Forecast
2014-2024: Future Prospects for Leading Companies
Table 5.5 Retail Prices of the Blood Glucose Meters and Strips Currently Available in
the Market, by Company, 2014
Company Meter Manufacturer's Suggested Retail Price
FreeStyle Freedom Lite Meter: $19.99 Strips: $1.46-$1.52/strip
FreeStyle InsuLinx Meter: $49.99 Strips: $1.54-$1.60/strip
FreeStyle Lite Meter: $19.99 Strips: $1.46-$1.52/strip
Precision Xtra Meter: $19.99 Strips: $1.46-$1.52/strip
Glucocard 01
Meter: Manufacturer declined to provide price
Strips: Manufacturer declined to provide price
Glucocard 01-mini
Meter: Manufacturer declined to provide price
Strips: Manufacturer declined to provide price
Glucocard Expression
Meter: Manufacturer declined to provide price
Strips: Manufacturer declined to provide price
Glucocard Vital
Meter: Manufacturer declined to provide price
Strips: Manufacturer declined to provide price
WaveSense Presto Meter: $34.99 Strips: 37¢/strip
WaveSense PrestoPro Meter: $38.83 Strips: 37¢/strip
Breeze2 Meter: $24.99 Strips: $1.04/strip
Contour Meter: $19.99 Strips: $1.24/strip
Contour Next Meter: $19.99 Strips: 83¢/strip
Contour Next EZ Meter: $19.99 Strips: 83¢/strip
Contour Next Link Meter: Sold only w ith pump Strips: 83¢/strip
Contour Next USB Meter: $29.99 Strips: 83¢/strip
Rightest GE100 Meter: $14.99 Strips: 72¢/strip
Rightest GM100 Meter: $9.99-$12.99 Strips: 34¢-50¢/strip
Rightest GM300 Meter: $7.99-$10.99 Strips: 26¢-30¢/strip
Rightest GM550 Meter: $11.99-$14.99 Strips: 32¢-50¢/strip
BioSense
Medical
Solus V2 Meter: $19.99 Strips: 40¢/strip
CVS Blood Glucose Monitor
Featuring Truetrack Smart System
Meter: $14.99 Strips: 53¢/strip
CVS True2go Glucose Test Meter Meter: $9.99 Strips: 70¢/strip
CVS Trueresult Blood Glucose Meter: $17.99 Strips: 70¢/strip
Diabetic
Supply of
Suncoast
Advocate Redi-Code Plus
Speaking Meter
Meter: $29.99 Strips: 50¢/strip
Entra Health
Systems
MyGlucoHealth Wireless Meter: $89.95 Strips: 99¢/strip
Fifty50 2.0 Meter: $39.95 Strips: 74¢/strip
Fifty50 2.0 Sport Meter: $39.95 Strips: 74¢/strip
Fora D10 Meter: $79.99 Strips: 80¢/strip
Fora D20 Meter: $99.99 Strips: 80¢/strip
Fora D30e/f Meter: $149.99 Strips: 80¢/strip
Fora D40a/b Meter: $159.99/$199.99 Strips: 80¢/strip
Fora G30 Meter: $39.99 Strips: 80¢/strip
Fora G31a/b Meter: $84.99/$124.99 Strips: 80¢/strip
Fora GD20 Meter: $34.99 Strips: 80¢/strip
Fora GD40a/b Meter: $69.99 Strips: 80¢/strip
Fora Premium V10 Meter: $49.99 Strips: 80¢/strip
Fora V12 Meter: $79.99 Strips: $1.60/strip
Fora V30 Meter: $49.99 Strips: 80¢/strip
Test N’ Go Meter: $149.99 Strips: $1.20/strip
Genesis
Health
Technologies
Genesis Meter Meter: $99.95 Strips: $1.08/strip
Bionime
Abbott
Diabetes
Care
Arkray
AgaMatrix
Bayer
CVS/
Pharmacy
Fora Care
Fifty50
Medical
Source: Diabetes Forecast 2014; Visiongain 2014
17. www.visiongain.com Page 236
The Point of Care Diagnostics Market Forecast
2014-2024: Future Prospects for Leading Companies
Figure 11.8 Siemens Healthcare Revenue Forecast: Revenue ($bn) and AGR (%), 2013-
2024
Source: Visiongain 2014
The outlook in terms of revenue looks promising for Siemens Healthcare in the near future. The
“Agenda 2013” initiative set up to increase its regional presence and competitiveness by improving
the cost position of the company’s Diagnostics business looks set to streamline its production
costs; leading to higher profits. Although Siemens Healthcare’s Diagnostics profit for fiscal 2013
was impacted by an increase in valuation allowances for receivables triggered by a debt rating
downgrade related to Greece, the diagnostics sector of the business will see year on year increase
in profits from 2014, Visiongain believes.
11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio
Siemens healthcare can be divided in: Healthcare IT & Infrastructure, Hearing Instruments,
Laboratory Diagnostics, Medical Imaging and Therapy Systems.
Siemens Healthcare Diagnostics provides point-of-care products and services that enable
healthcare providers to render better patient management and help ensure optimized clinical
outcomes.
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
0
5
10
15
20
25
30
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR(%)
Sales$bn
Year
Siemens Revenue ($bn) AGR (%)
